Stock Events

Stock Events

Neurocrine Biosciences 

$152.25
171
+$2.66+1.78% Friday 20:00

Statistics

Day High
154.74
Day Low
149.59
52W High
155.63
52W Low
109.68
Volume
1,205,558
Avg. Volume
-
Mkt Cap
15.28B
P/E Ratio
28.16
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
0.08
0.73
1.39
2.04
Expected EPS
1.563955
Actual EPS
N/A

Financials

16.73%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
5.72BRevenue
957.2MNet Income

Analyst Ratings

183.88Average Price Target
The highest estimate is 246.00.
From 17 ratings within the last 6 months. This is not an investment recommendation.
Buy
82%
Hold
18%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NBIX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie competes in the neurology and psychiatry market, particularly with treatments for Parkinson's disease, directly competing with Neurocrine's offerings.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.7B
Teva Pharmaceutical has a strong focus on CNS (Central Nervous System) disorders, including treatments for movement disorders, making it a direct competitor.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.76B
Acadia Pharmaceuticals offers products for CNS disorders, including Parkinson’s disease psychosis, competing in Neurocrine's market space.
Alkermes
ALKS
Mkt Cap5.69B
Alkermes competes in the area of CNS disorders, with a focus on schizophrenia and bipolar disorder, overlapping with Neurocrine's psychiatric disorder treatments.
AMGEN
AMGN
Mkt Cap178B
Amgen has a broad portfolio that includes treatments for neurological disorders, potentially competing with Neurocrine's neurology-focused therapies.
Biogen
BIIB
Mkt Cap27.62B
Biogen focuses on neurology, with treatments for multiple sclerosis and spinal muscular atrophy, indicating a competitive overlap in the neurology space.
Luna Innovations
LUNA
Mkt Cap52.05M
Lundbeck specializes in psychiatric and neurological disorders, including treatments for depression and Parkinson’s, competing with Neurocrine's portfolio.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. has a diversified portfolio that includes treatments for neurological conditions, potentially competing with Neurocrine.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a broad range of treatments, including for neurological conditions, making it a competitor in the neurology and psychiatry market.

About

There is no Profile data available for NB3.MU.
Show more...
CEO
Mr. Kyle W. Gano Ph.D.
Employees
1800
Country
United States
ISIN
US64125C1099

Listings

MI
IT
1NBIX.MI
MX
MX
NBIX.MX
STU
DE
NB3.STU
SA
BR
N1BI34.SA

0 Comments

Share your thoughts

FAQ

What is Neurocrine Biosciences stock price today?▼
The current price of NBIX is $152.25 USD — it has increased by +1.78% in the past 24 hours. Watch Neurocrine Biosciences stock price performance more closely on the chart.
What is Neurocrine Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Neurocrine Biosciences stocks are traded under the ticker NBIX.
Is Neurocrine Biosciences stock price growing?▼
NBIX stock has risen by +15.53% compared to the previous week, the month change is a +15.66% rise, over the last year Neurocrine Biosciences has showed a +31.58% increase.
What is Neurocrine Biosciences market cap?▼
Today Neurocrine Biosciences has the market capitalization of 15.28B
When is the next Neurocrine Biosciences earnings date?▼
Neurocrine Biosciences is going to release the next earnings report on August 04, 2026.
What were Neurocrine Biosciences earnings last quarter?▼
NBIX earnings for the last quarter are 1.91 USD per share, whereas the estimation was 1.22 USD resulting in a +57.05% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Neurocrine Biosciences revenue for the last year?▼
Neurocrine Biosciences revenue for the last year amounts to 5.72B USD.
What is Neurocrine Biosciences net income for the last year?▼
NBIX net income for the last year is 957.2M USD.
How many employees does Neurocrine Biosciences have?▼
As of May 09, 2026, the company has 1,800 employees.
In which sector is Neurocrine Biosciences located?▼
Neurocrine Biosciences operates in the Health & Wellness sector.
When did Neurocrine Biosciences complete a stock split?▼
Neurocrine Biosciences has not had any recent stock splits.
Where is Neurocrine Biosciences headquartered?▼
Neurocrine Biosciences is headquartered in San Diego, United States.